Antifungal prophylaxis of patients undergoing allogenetic hematopoietic stem cell transplantation in China: a multicenter prospective observational study

Table 5 Risk factors for proven/probable IFD among allo-HSCT patients in SAP group

Factor	Univariate analysis			Muitivariate analysis
Factor	Patients with proven/probable IFD (n/N)	Incidence of proven/probable IFD (%)	Comparison (P value)	SE	OR (95 % CI)	Comparison (P value)
Transplantation type
HLA-matched related (sibling)	1/35	2.86	0.08
Haploidentical	5/26	19.23		1.77	2.48 (0.08–79.46)	0.61
Unrelated	4/27	14.81		1.77	2.24 (0.07–72.11)	0.65
Antithymocyte globulin
Yes	9/52	17.31	0.04	1.68	2.49 (0.09–67.66)	0.59
No	1/36	2.78
Prolonged, profound neutropenia
ANC > 500/mm³	0/1	0.00	0.23	1.13	5.90 (0.65–53.89)	0.12
ANC < 500/mm³, <10 days	1/18	5.56
ANC < 500/mm³, 10–14 days	0/17	0.00
ANC < 500/mm³, >14 days	9/52	17.31
Liver impairment
Yes	5/24	20.83	0.12	0.74	2.07 (0.49–8.79)	0.33
No	5/64	7.81
Time of IFD prophylaxis
<35 days	5/40	12.50	1.00	0.76	1.10 (0.25–4.86)	0.90
≥35 days	5/48	10.42
Drugs for IFD prophylaxis
Fluconazole/itraconazole/	3/27	11.11	1.00	0.96	0.87 (0.13–5.64)	0.88
Fluconazole + itraconazole^b
Voriconazole^b	4/32	12.50		0.91	1.50 (0.25–8.96)	0.66
Others^a	3/29	10.34

^aIncluding voriconazole + caspofungin and fluconazole + caspofungin + voriconazole
^bCompared with others
The italicized data reflected significant difference

ISSN: 1756-8722